Roivant Sciences

ROIV

New York, United Kingdom· Est. 2019

roivant.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ROIV · Stock Price

USD 28.28+17.64 (+165.79%)

Market Cap: $20.3B

Historical price data

Overview

Roivant Sciences' mission is to improve health by rapidly delivering innovative medicines through its unique 'Vant' model—nimble, entrepreneurial subsidiaries. The company has demonstrated significant execution with 12 positive Phase 3 trials, 8 FDA approvals, and a successful commercial launch of VTAMA® for plaque psoriasis, which was subsequently acquired by Organon in 2024. Its strategy centers on decentralized decision-making, specialized expertise, and disciplined capital allocation to de-risk development and maximize value creation across a broad pipeline in autoimmune, pulmonary, and other diseases.

Autoimmune DiseasesPulmonary DiseasesDermatology

Technology Platform

The 'Vant' model: a decentralized organizational and operational platform that creates nimble, focused subsidiary companies with aligned incentives, enabling rapid decision-making and disciplined capital allocation across a diversified pipeline.

Pipeline

2 drugs in pipeline

Drug	Indication	Stage	Watch
Gimsilumab + Placebo	COVID-19	Phase 2
Ketamine + Placebo	Autism Spectrum Disorder	Phase 1

Funding History

Total raised:$1.5B

PIPE$200MViking Global InvestorsMay 15, 2021

Series B$1.1BSoftBank Vision FundJul 15, 2017

Series A$200MViking Global InvestorsJan 15, 2015

Opportunities

Near-term catalysts include NDA submission for brepocitinib in dermatomyositis and pivotal data for IMVT-1402, which could drive significant revenue growth.

The Vant model provides a scalable framework to continuously incubate new companies and assets, offering long-term pipeline expansion beyond current lead programs.

Risk Factors

High dependence on lead assets brepocitinib and IMVT-1402; clinical or regulatory setbacks would be materially damaging.

Commercial execution in competitive markets like FcRn inhibitors remains unproven.

The decentralized 'Vant' model, while a strength, may face coordination and dilution challenges as the portfolio scales.

Competitive Landscape

Faces competition from approved JAK inhibitors and newer TYK2 drugs (e.g., BMS's Sotyktu) in brepocitinib's space, and from established FcRn blockers (e.g., argenx's Vyvgart) for IMVT-1402. Roivant's primary competitive edge is its operational 'Vant' model, which enables faster, more focused execution compared to large pharma and more disciplined capital allocation than many biotechs.